Skip to main content
. 2023 Mar 29;11(4):755. doi: 10.3390/vaccines11040755

Figure 3.

Figure 3

Antibody-dependent enhancement (ADE) of ZV1 glycovariants for DENV and ZIKV infection. Serial dilutions of ZV1 glycovariants were mixed with DENV-2 (A) or ZIKV (B) and then incubated with FcγRIIa+ K562 cells. After incubation, cells were fixed, permeabilized, and stained with an anti-flavivirus E antibody and then analyzed by flow cytometry to identify DENV-2 or ZIKV-infected cells. Results (Mean ± SD) from at least two independent experiments with technical triplicates for each sample are presented.